SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): January 29, 2013
(Exact Name of Registrant as Specified in its Charter)
Registrant’s telephone number, including area code: (646) 218-1450
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Alliqua, Inc. (the "Company") is announcing a strategic realignment of the senior executive team. On January 30, 2013, the Alliqua Board of Directors elected David Johnson, who joined the Board in December, 2012 and is currently the executive chairman of AquaMed Technologies, Inc., a wholly-owned subsidiary of the Company, to the position of chief executive officer of Alliqua, Inc.
Concurrently, James Sapirstein, who had been the chief executive officer of Alliqua, Inc., will become the chief executive officer of Alliqua BioMedical Inc., the Company’s wholly-owned subsidiary focused on introducing new active pharmaceutical ingredients into its hydrogel technology for the topical delivery of local and systemic therapies.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.